WHI-P97 - JAK 抑制劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEWHI-P97Cat. No.: HY-11067CAS No.: 211555-05-4分式: CHBrNO分量: 455.1作靶點(diǎn): JAK作通路: Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 5.88 mg/mL (12.92

2、mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 0.59 mg/mL (1.30 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 0.59 mg/mL (1.30 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 WHI-P97是JAK-3抑制劑。IC50 & Target JAK311

3、M (IC50)戶使本產(chǎn)品發(fā)表的科研獻(xiàn) SSRN. 2019 Apr. Harvard Medical School LINCS LIBRARYSee more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Ji KA, Yang MS, Jou I, Shong MH, Joe EH.Thrombin induces expression of cytokine-induced SH2 protein (CIS) in rat brain astrocytes:involvement of phospholipase

4、 A2, cyclooxygenase, and lipoxygenase.Glia. 2004 Nov 1;48(2):102-11.2. Wong WS, Leong KP.Tyrosine kinase inhibitors: a new approach for asthma.Biochim Biophys Acta. 2004 Mar 11;1697(1-2):53-69.3. Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, Navara CS, Narla RK.Structure-based design of

5、 novel anticanceragents.Curr Cancer Drug Targets. 2001 May;1(1):59-71.4. Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, Uckun FM.Structure-based design of specific inhibitors of Janus kinase 3as apoptosis-inducing antileukemic agents.Clin Cancer Res. 1999 Jun;5(6):1569-82.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-